Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang(Shanxi Medical University), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention)
Cited by 1,507
Related Papers
Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome
|The Lancet|2013|839
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311